Summary We have investigated the incidence of Gorlin syndrome (GS) in patients with the childhood brain tumour, medulloblastoma. One hundred and seventy-three consecutive cases of medulloblastoma in the North-West Regional Health Authority between 1954 and 1989 (Manchester Regional Health Board before 1974 were studied. After review of case notes, X-rays and health surveys only 2/173 cases had evidence supporting a diagnosis of GS. A further case at 50% risk of GS died of a brain tumour aged 4 years. The incidence of GS in medulloblastoma is, therefore, probably between 1-2%. A population based study of GS in the region started in 1983 was used to assess the incidence of medulloblastoma in GS, which was found to be between 3-5%. This figure is lower than previous estimates, but this is the first population based study undertaken. In view of the early age of onset in GS (mean 2 years) children presenting with medulloblastoma, especially under 5 years, should be examined for signs of the syndrome. Those at high risk of developing multiple invasive basal cell carcinomata will then be identified.
Gorlin or Naevoid Basal Cell Carcinoma syndrome was first delineated in 1960 (Gorlin & Goltz) . It is an autosomal dominant condition characterised by the development of multiple basal cell carcinomata and jaw cysts. Skeletal anomalies are very common (Gorlin, 1987) . Calcification of the falx cerebi occurs early in life in 85% and bridging of the sella turcica in 60-80% (normal 5% and 4%). Rib abnormalities, especially bifid rib is present in 60% and vertebral anomalies in 40%. Short fourth metacarpal is present in 15-40%, but this is a less reliable sign due to its rather high incidence (10%) in the normal population. Children with the condition often have a birth weight and head circumference above the 97th centile. There have been over 30 reports of medulloblastoma in GS or their first degree relatives. Estimates of its incidence in GS have been as high as 20% (Chan & Little, 1983) . Patients receiving craniospinal radiotherapy after tumour diagnosis develop multiple invasive basal cell carcinomata in the radiation field 6 months to 3 years after treatment (Strong, 1977) . Experience with one such case (Evans et al., 1991) led us to undertake a population based study to assess the incidences of medulloblastoma in GS and GS in medulloblastoma. (Birch, 1988 A population based study of GS was undertaken for the North-West region in 1983 (Farndon, 1988) . All dermatological, oral surgery and plastic surgery departments were approached for patients. As a result of this study and further attempts to ascertain patients in the last year through a regional GS register set up in March 1990, we have identified 73 living cases from 29 families. An extensive pedigree was constructed on each family and in each case nearly all at risk relatives were interviewed, examined and X-rayed. A family history of tumours or early deaths was particularly sought. we could review lateral skull X-rays. Apart from the two with GS a further two had bridging of the sella turcica. However they were both over 7 years at diagnosis, had no abnormalities on CXR and were both alive at the time of the study with no other evidence of GS. Spinal X-rays were available in 66 and checked in 47, the only gross congenital abnormality was a sacral spina bifida occulta in one case, there was no supporting evidence for GS and she was 10 years old at diagnosis. Bone age X-rays were performed in many cases, these could be reviewed in 47, none of which showed short 4th metacarpals. In only 25/173 cases was there no radiological data and in only six of the most recent 100 cases.
Subjects and methods

Results
Medulloblastoma study
All records were particularly analysed for dermatological problems. The two cases of GS both developed basal cell carcinomata. Among the other cases, two had skin disease which caused problems. One patient had a resistant seborrheic dermatitis on the scalp which had cleared completely at the time of death 61 months after radiotherapy. Another patient developed granulomas on the back which resolved spontaneously, the skin is clear 13 years after treatment. A total of 78 patients survived to 3 years after radiotherapy, an interval during which they may be expected to have developed basal cell carcinomata (Strong, 1977) .
Post mortem findings were available on 28 of the cases that died. No evidence supporting a diagnosis of GS was found in any of these. Both cases of GS had developed jaw keratocysts in the second decade, but no other case could be found. The first case presented aged 29 months and eventually died 30 years after his medulloblastoma having had over 70 operations for basal cell carcinomata (Evans et al., 1991) . The second case was diagnosed aged 15 months and is still alive 23 years after diagnosis. Both cases were mentally retarded. Only 7/173 of the medulloblastoma patients had insufficient data to reduce their risk of having GS. Their ages were 74, 11, 7, 151, 177, 133 and 4 months, respectively. Population based study of GS A total of 29 families were identified and included 72 living individuals with GS. This represents a prevalence of 1:56,000 for the population studied. By extrapolating the pedigrees back to those alive in the period 1954 to 1989, we could find at least 84 cases. In all but 3/72 living cases there was some evidence of GS in one or other of their parents. The proportion caused by new mutation of the GS gene in our study population may be as low as 4.17%. Only two cases did not live long enough to have medulloblastoma. The first died of cardiac fibromata in the neonatal period and the second of extreme prematurity. The two cases of medulloblastoma were also ascertained by this population based study. A third probable case of medulloblastoma occurred in a 4 year old boy who died of a posterior fossa tumour found on CT scan. He was at 50% risk of GS as his mother is a known case, unfortunately he died preoperatively and post-mortem was refused.
Literature review
There have been at least 37 reports of GS in association with medulloblastoma. Gorlin et al. (1965) referred to three cases he had heard of by personal communication. There were no details of these cases and two other cases (Rayner et al., 1977; Woolgar et al., 1987) who were noted to have died of the disease and had relatives with GS, also had no further details. The details of those surviving (Table I) and those cases noted to have died from the disease (Table II) are presented. Several cases have been reported twice (Neblett et al., 1971; Anderson & Cook, 1966; Taylor et al., 1968) . The average age of onset in those surviving was 2.11 years. When our two cases are added this gives an average age of diagnosis of 2.08 in 20 cases. Those who died usually only had that date given, so the average age for death in these individuals was 3.46 years. Sixteen/18 survivors were noted to develop basal cell carcinomas in the radiation field within 9 years. The two remaining cases were only 1 and 4 years post-radiotherapy at the time the articles were written.
Discussion
The association between GS and medulloblastoma is well established by the large number of reports of the two rela- (Chan & Little, 1983) . There has been no population based study, until now, to estimate the true figure. Difficulties in coming to an accurate estimate have been due to inability to diagnose GS in those patients who have died of tumour, before they would have manifested features of GS. We have found sufficient data in at least 80% of our cases to make a diagnosis of GS unlikely. At least 90% of individuals with GS manifest a radiologically detectable abnormality. The only failing of our available radiological data is that those patients who died under 10 years may not yet have developed calcification on skull X-ray. We would expect those with GS to develop tumour at an average age of 2 years. However it is likely that the gene would manifest itself in at least one other way and indications are that those with GS run a more benign course and are more likely to survive (Gorlin, 1987) . Those surviving at least 3 years are likely to have basal cell carcinomas in the radiation field. Although previous papers refer to this complication as late as 9 years after therapy they do not mention when they first occurred.
Other indicators such as high birthweight were not useful in identifying cases. Although the average birthweight was high 3690 g ( + 0.51 s.d.) and more cases than expected had a weight above the 97th centile (4/71), the extreme cases could be excluded on other grounds such as age of onset.
The medulloblastoma series is particularly strong in that it is supported by a population based study of GS which is likely to have a high level of ascertainment. The two definite and one likely case were all also identified by this means. Any cases of medulloblastoma which did have GS, would have to be from families we have not identified, or occur as new mutations. Both of these are unlikely due to our high ascertainment and low mutation rates. Only 3/173 cases had no real data and occurred at ages compatible with GS. The incidence of medulloblastoma in our GS population was 3/84 (3.6%). In view of the high level of ascertainment achieved by the MCTR the third case could be added to the statistics without much adjustment. This would give an incidence of GS in medulloblastoma of 1-2%.
We have presented a population based series of medulloblastoma and GS which has given the first accurate estimate of their associations. It is important to identify those individuals with medulloblastoma who have GS, as it may alter the way in which radiotherapy is administered, to diminish any unnecessary skin exposure. Suspicion should be higher the younger the patient. Although only 1-2% had GS in the whole series this represented 4.5% of those under 5 years and 5% of those under 3 years. A diagnosis of GS will alert the clinican to the almost inevitable crop of basal cell carcinomata, which can then be managed optimally. Other complications, such as jaw cysts, could be anticipated by regular dental screening (orthopantograms). It may also result in further family members with GS being identified. Finally, those families known to have GS should have any new issue checked for features of the condition. Those at risk should have regular neurological checks (6 monthly for first 3 years then annually until 7 years) and where any doubt exists a brain scan should be arranged.
